Thomas C. Weber

Ernst Grube Str. 40
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal: Journal of hematology & oncology
Published: April 06, 2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Journal: Lancet (London, England)
Published: February 19, 2026

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Journal: Leukemia
Published: February 08, 2026

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

Journal: HemaSphere
Published: October 27, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances
Published: September 15, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances
Published: September 15, 2025

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Journal: Leukemia
Published: July 25, 2025

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Journal: Blood advances
Published: December 23, 2024

Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Journal: Nature communications
Published: March 26, 2024

T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.

T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.

Journal: Haematologica
Published: March 01, 2024

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Journal: Haematologica
Published: February 06, 2024

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 06, 2023
Showing 1-12 of 45

Last Updated: 09/26/2026